Welcome to our dedicated page for SAB BIOTHERAPEUTICS news (Ticker: BCYPU), a resource for investors and traders seeking the latest updates and insights on SAB BIOTHERAPEUTICS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SAB BIOTHERAPEUTICS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SAB BIOTHERAPEUTICS's position in the market.
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company, will host a virtual R&D Day on October 13, 2021, at 10:00 a.m. ET. The event aims to showcase its DiversitAb™ platform and various clinical programs. Notable speakers include Arturo Casadevall from Johns Hopkins and Michael Haller from the University of Florida. Additionally, SAB announced a planned merger with Big Cypress Acquisition Corp. (NASDAQ: BCYP), expected to finalize in Q4 2021. For more details, visit www.sabbiotherapeutics.com.
SAB Biotherapeutics announced the dosing of the first patient with SAB-185 in the Phase 3 ACTIV-2 trial for non-hospitalized patients with mild to moderate COVID-19. This polyclonal antibody therapeutic has shown potential in neutralizing SARS-CoV-2 variants.
The Phase 3 trial, assessing SAB-185 against active controls, aims to enroll approximately 1,200 participants. The trial's primary endpoint includes safety and non-inferiority for preventing hospitalization or death through day 28.
SAB Biotherapeutics has appointed Russell Beyer as chief financial officer, effective September 20, 2021. With over 25 years of experience in financial operations at major pharmaceutical companies, Beyer aims to enhance SAB's financial growth. The company is advancing its candidate, SAB-185, into a Phase 3 trial, as part of a broader pipeline targeting various diseases. This leadership change coincides with SAB's planned merger with Big Cypress Acquisition Corp, expected to close in the fourth quarter of 2021, potentially strengthening SAB's financial position.
SAB Biotherapeutics announced that its immunotherapy candidate SAB-185 has advanced to Phase 3 of the ACTIV-2 trial, after meeting pre-defined efficacy goals during a Phase 2 interim analysis. This decision was recommended by an independent Data Safety Monitoring Board, based on positive evidence from safety and efficacy studies.
The Phase 3 trial aims to analyze the clinical safety and efficacy of SAB-185 for treating non-hospitalized patients with mild to moderate COVID-19, with approximately 1,200 participants planned.
SAB Biotherapeutics received an additional
SAB Biotherapeutics has completed enrollment in its Phase 2a clinical trial for SAB-176, aimed at evaluating the safety and efficacy of this novel anti-influenza immunotherapy. The trial involves 60 healthy adults challenged with a pandemic influenza strain, with expected topline data in 4Q2021. The company also announced a planned merger with Big Cypress Acquisition Corp. (NASDAQ: BCYP), expected to close in Q4 2021. SAB-176 is designed to offer broad protection against influenza A and B strains, potentially improving treatment efficacy for high-risk populations.
SAB Biotherapeutics has announced that its co-founder, Eddie J. Sullivan, PhD, will present at two virtual investor conferences in September. The first is the H.C. Wainwright 23rd Annual Global Investment Conference from September 13 to December 12, featuring pre-recorded presentations. The second is the Baird Global Healthcare Conference on September 14, with a fireside chat format. Additionally, SAB plans to merge with Big Cypress Acquisition Corp. (NASDAQ: BCYP) in Q4 2021, enhancing its clinical-stage biopharmaceutical initiatives.
Big Cypress Acquisition Corp. announced that, starting February 9, 2021, holders of its initial public offering's 11,500,000 units can separately trade common stock and redeemable warrants. The units will continue to trade under the symbol BCYPU, while the common stock and warrants will trade under BCYP and BCYPW, respectively. Holders must contact their brokers for the separation process. Ladenburg Thalmann acted as the sole book running manager, with Brookline Capital Markets as co-manager. The SEC declared the relevant registration statement effective on January 11, 2021.
Big Cypress Acquisition Corp. completed its initial public offering, closing on January 14, 2021, with 11,500,000 units sold at $10.00 per unit. The offering garnered total gross proceeds of $115,000,000. Each unit comprises one share of common stock and one-half of a redeemable warrant. The units began trading on Nasdaq under the symbol BCYPU on January 12, 2021. Ladenburg Thalmann served as sole book running manager of the offering, with legal counsel provided by Dentons US LLP and Graubard Miller.
Big Cypress Acquisition Corp. has announced the pricing of its initial public offering (IPO) of 10 million units at $10.00 each, with trading set to begin on Nasdaq under the symbol BCYPU on January 12, 2021. Each unit comprises one common stock share and half a redeemable warrant, with a warrant exercise price of $11.50. The offering is expected to close on January 14, 2021. The company, focusing on business combinations in the life sciences sector, has granted underwriters a 45-day option to purchase an additional 1.5 million units.
